412.4: Outcomes of Sodium–Glucose Cotransporter 2 Inhibitors And Glucagon-like Peptide-1 Receptor Agonists in Diabetic Kidney Transplant Recipients

Mahmoud, Tarek A.; Yagan, Jude; Hasan, Amal; Gheith, Osama; Mostafa, Mohamed; Rida, Suzzan; El-Serwi, Nabil; Shaker, Mohamed; Khalid, Mahmoud; Nair, Prasad; Al-Otaibi, Torki

doi:10.1097/01.tp.0000887616.86686.ae

Cited by 2 publications

(28 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the authors’ opinion, SGLT2i use in diabetic kidney transplant recipients appears safe and effective in selected candidates. Based on currently available literature, optimal use of SGLT2i in kidney transplant recipients with pre-existing diabetes or PTDM is suggested in Table 2 ( 12 , 19 , 25 – 29 ). The routine recommendation for SGLT2i use in diabetic and non-diabetic kidney transplant recipients for their potential cardio- and reno-protective effects awaits further studies.…”

Section: Discussionmentioning

confidence: 99%

Optimal use of SGLT2 inhibitors in diabetic kidney transplant recipients

Pham

Pham²

2022

Front. Nephrol.

View full text Add to dashboard Cite

Sodium-glucose cotransporter 2 inhibitor (SGLT2i), a glucosuric agent initially approved for use as an antidiabetic agent, was unexpectedly found to confer cardio-and reno-protective effects in individuals with or without type 2 diabetes mellitus. Despite mounting evidence suggesting that SGLT2i provides cardio- and reno-protective benefits in both diabetic and non-diabetic and in chronic kidney disease (CKD) patients in the general population, reservations for its use in the transplant setting persist due to concerns for increased risk of genital mycotic and urinary tract infections. A comprehensive review of the literature on the efficacy and safety of SGLT2i use in diabetic kidney transplant recipients is herein presented followed by authors’ opinion on its optimal use in this patient population.

show abstract

Section: Discussionmentioning

confidence: 99%

Optimal use of SGLT2 inhibitors in diabetic kidney transplant recipients

Pham

Pham²

2022

Front. Nephrol.

View full text Add to dashboard Cite

show abstract

“…The characteristics of the included studies are described in Tables 1 and 2. Fifteen studies (75%) were in kidney transplant recipients 16,[19][20][21][22][23][24][25][26][27][28][29][30][31][32] ; one of the studies included two patients that were kidney/pancreas and kidney/liver recipients. 25 Four studies (26%) were in heart transplant recipients.…”

Section: Study Characteristicsmentioning

confidence: 99%

“…All studies included patients with a diagnosis of type 2 DM, and 17 (85%) of the studies also included patients with post-transplant DM. 16,[19][20][21][22][24][25][26][27][28][29][30][31][32][33][34]37 The most frequently assessed SGLT2 inhibitor was empagliflozin in 16 of the 20 studies (80%). 16,[19][20][21]23,24,[26][27][28][29]31,[33][34][35]37 At baseline, all of the studies either allowed for inclusion of patients…”

Section: Study Characteristicsmentioning

confidence: 99%

“…20,23,25,31 Sixteen out of the 20 studies (80%) reported time to initiation of an SGLT2 inhibitor. 16,[19][20][21][22][25][26][27][28][29][31][32][33][34][35]37 Of the studies that reported it, the average time from transplant to initiation of an SGLT2 inhibitor was about 4.5 years (range of 0.25-9.6 years). Nineteen of the 20 studies (95%) reported a planned follow-up time or the average follow-up time in the study.…”

Section: Ta B L E 1 (Continued)mentioning

confidence: 99%

“…Nineteen of the 20 studies (95%) reported a planned follow-up time or the average follow-up time in the study. 16,[19][20][21][22][23][24][26][27][28][29][30][31][32][33][34][35][36][37] Of the studies that reported it, the average follow-up time was about 13 months (range of 4 weeks to 63 months).…”

Section: Ta B L E 1 (Continued)mentioning

confidence: 99%

See 2 more Smart Citations

The efficacy and safety of sodium‐glucose cotransporter‐2 inhibitors in solid organ transplant recipients: A scoping review

Mreyoud,

Walter,

Wilpula

et al. 2024

Pharmacotherapy

View full text Add to dashboard Cite

Sodium glucose co‐transporter 2 (SGLT2) inhibitors are used for the treatment of diabetes and for their cardiovascular and kidney benefits in patients with or without diabetes. Use in solid organ transplant recipients is controversial because transplant recipients were excluded from the major clinical trials assessing SGLT2 inhibitors. The goal of this review was to assess the available literature regarding the use of SGLT2 inhibitors in solid organ transplant recipients. A PubMed search was conducted for studies published in English through December 31, 2023. Studies were excluded if they were meta‐analyses, review articles, commentaries, single case reports, or in vitro studies, or did not involve the use of SGLT2 inhibitors in solid organ transplant recipients with a diabetic, cardiovascular, or kidney outcome being assessed. In the final review, 20 studies were included: kidney (n = 15), heart (n = 4), and liver/lung/kidney (n = 1) transplant recipients. SGLT2 inhibitors had similar A1c reduction efficacy and were found to be weight neutral with possible weight reduction effects. Cardiovascular and kidney outcomes were not adequately assessed in the available studies. Adverse effects were reported to occur at a similar rate in transplant recipients compared to the general population. SGLT2 inhibitors were initiated ≥1‐year post‐transplant in most transplant recipients included in these studies. The overall safety and antihyperglycemic efficacy of SGLT2 inhibitors in kidney and heart transplant recipients is similar to the general population. Data assessing SGLT2 inhibitors use in solid organ transplant recipients for longer durations are needed.

show abstract

412.4: Outcomes of Sodium–Glucose Cotransporter 2 Inhibitors And Glucagon-like Peptide-1 Receptor Agonists in Diabetic Kidney Transplant Recipients

Cited by 2 publications

References 0 publications

Optimal use of SGLT2 inhibitors in diabetic kidney transplant recipients

Optimal use of SGLT2 inhibitors in diabetic kidney transplant recipients

The efficacy and safety of sodium‐glucose cotransporter‐2 inhibitors in solid organ transplant recipients: A scoping review

Contact Info

Product

Resources

About